Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

The primary end point, major pathologic response (MPR), was reviewed per consensus criteria and centrally confirmed: In the monotherapy arm, the MPR rate was 33.3%, with all responses being pathologic ...

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this space.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...